IceCure Medical's ProSense Featured at SIO Meeting Amid FDA Decision Anticipation
Ticker: ICCM · Form: 6-K · Filed: Feb 4, 2025 · CIK: 1584371
Sentiment: neutral
Topics: medical-devices, regulatory-update, conference
Related Tickers: ICCM
TL;DR
IceCure Medical's ProSense system gets spotlight at SIO meeting, awaiting FDA decision for breast cryoablation.
AI Summary
On February 4, 2025, IceCure Medical Ltd. announced its ProSense system was featured at the Society of Interventional Oncology (SIO) Annual Meeting. The company had an award-winning abstract and offered hands-on training for breast cryoablation, as the medical community awaits a potential FDA market authorization decision.
Why It Matters
The company's participation and the anticipation of FDA approval for its ProSense system could significantly impact its market access and adoption in the US for breast cryoablation procedures.
Risk Assessment
Risk Level: medium — The company is awaiting FDA market authorization, which introduces regulatory risk and uncertainty regarding future revenue streams.
Key Players & Entities
- IceCure Medical Ltd. (company) — Registrant
- ProSense (product) — Company's cryoablation system
- Society of Interventional Oncology (SIO) Annual Meeting (event) — Conference where the company was featured
- February 4, 2025 (date) — Date of the press release
- FDA (organization) — Regulatory body whose decision is anticipated
FAQ
What was the main focus of IceCure Medical's presence at the SIO Annual Meeting?
The company's ProSense system was featured, including an award-winning abstract and hands-on training for breast cryoablation.
What regulatory decision is the medical community and IceCure Medical anticipating?
They are anticipating the FDA's market authorization decision for the ProSense system.
When was the press release regarding the SIO meeting issued?
The press release was issued on February 4, 2025.
What is the primary product highlighted in the filing?
The primary product highlighted is IceCure Medical's ProSense system, used for cryoablation.
What type of report is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 350 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-02-04 08:35:17
Filing Documents
- ea0229812-6k_icecure.htm (6-K) — 12KB
- ea022981201ex99-1_icecure.htm (EX-99.1) — 18KB
- 0001213900-25-009702.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: February 4, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3